SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001485003-16-000153
Filing Date
2016-08-19
Accepted
2016-08-19 16:12:12
Documents
4
Period of Report
2016-08-15
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebioform8kproformaresultsb.htm 8-K 59522
2 EXHIBIT 99.1 elevenbio-pressreleaseclos.htm EX-99.1 11155
3 EXHIBIT 99.2 proformafinancials.htm EX-99.2 241413
4 ebiologoa09.jpg GRAPHIC 89522
  Complete submission text file 0001485003-16-000153.txt   436623
Mailing Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142 617-871-9911
Eleven Biotherapeutics, Inc. (Filer) CIK: 0001485003 (see all company filings)

IRS No.: 252025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36296 | Film No.: 161843302
SIC: 2834 Pharmaceutical Preparations